Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
GENB · NASDAQ · Pharmaceutical Preparations · No 10-K yet
$9.84−0.65 (−6.20%)
Close of Nov 17, 2026, vs Nov 16 · end-of-day, not a live quote
Generate Biomedicines (GENB) · oqro.io/stocks/GENB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Fund moves · Holdings as of Sep 30, 2026 (Q3 2026) · Filed Nov 13, 2026
ARK Investment Management disclosed an increased position in GENB for Q3 2026Source5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 5, 2026
FMR LLC now owns 5.6% of GENB as a passive investorSourceInsider trade · Traded Oct 29, 2026 · Filed Nov 4, 2026
Director sold ~$185K of GENB shares in the open marketSourcePlanned sale · Planned for Oct 29, 2026 · Notice filed Oct 29, 2026
Director filed to sell about $185K of GENB stockSourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Deep Track Capital, LP disclosed a new position in GENB for Q2 2026SourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
ARK Investment Management disclosed an increased position in GENB for Q2 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 14, 2026
Siren, L.L.C. disclosed a new position in GENB for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 12, 2026
ARK Investment Management disclosed a new position in GENB for Q1 2026Source